Australia Markets closed

IQVIA Holdings Inc. (IQV)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
198.89+3.94 (+2.02%)
At close: 04:04PM EDT
198.11 -0.78 (-0.39%)
After hours: 04:43PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close194.95
Open196.43
Bid198.11 x 1300
Ask206.21 x 1300
Day's range194.91 - 198.89
52-week range165.75 - 254.94
Volume950,316
Avg. volume983,425
Market cap36.942B
Beta (5Y monthly)1.39
PE ratio (TTM)94.71
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Global Clinical Trial Activity Remained Resilient in 2022 Despite The Continued Pandemic, Says IQVIA Institute

    RESEARCH TRIANGLE PARK, N.C., March 14, 2023--In 2022, global clinical trial activity remained resilient even as the COVID-19 pandemic stretched through the year, with a 1% decline in non-COVID trial activity compared to 2021. COVID-19 trials as a percentage of total trial activity dropped from 10% to 6% of the 5,756 total trials run in 2022. Non-COVID trial activity increased by 8% between 2019 and 2022, suggesting a restoration to pre-pandemic growth rates, according to a new report, Global Tr

  • Business Wire

    IQVIA CFO Ron Bruehlman to Speak at Barclays Global Healthcare Conference on March 15, 2023

    RESEARCH TRIANGLE PARK, N.C., March 01, 2023--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Barclays Global Healthcare Conference in Miami, FL on Wednesday, March 15, 2023 at 9:30 a.m. ET.

  • Business Wire

    IQVIA Publishes its 2022 Environmental, Social and Governance Report

    RESEARCH TRIANGLE PARK, N.C., February 23, 2023--IQVIA (NYSE:IQV) has published its 2022 Environmental, Social and Governance (ESG) Report. The annual report provides a detailed account of the organization’s focus on reducing its environmental impact and commitment to accelerating positive outcomes for public health and patients.